[New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].

Subjects

Subjects :

Drug Approval
Humans
Immunotherapy, Adoptive adverse effects
Lymphoma, Follicular drug therapy
Lymphoma, Large B-Cell, Diffuse drug therapy
Lymphoma, Large B-Cell, Diffuse pathology
Lymphoma, Non-Hodgkin drug therapy

Details

Language :

French

ISSN :

1769-6917

Volume :

109

Issue :

9

Database :

MEDLINE

Journal :

Bulletin du cancer

Publication Type :

Editorial & Opinion

Accession number :

35717220

Full Text :

https://doi.org/10.1016/j.bulcan.2022.04.020